WASHINGTON - U.S. biotechnology firm Moderna Inc. said Wednesday new clinical data on an experimental coronavirus vaccine showed effectiveness against the Omicron variant, making it the company's lead candidate for distribution as a fall booster shot.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
